期刊文献+

重组人p53腺病毒联合顺铂治疗肺癌所致胸腔积液疗效观察 被引量:3

下载PDF
导出
摘要 目的观察研究重组人p53腺病毒联合顺铂治疗肺癌所致胸腔积液的临床应用价值。方法肺癌致胸腔积液患者47例,完全随机分成联合组(顺铂+重组人p53腺病毒组22例)和单药组(顺铂组25例)。2组分别经胸腔置管向胸腔灌注重组人p53腺病毒和顺铂,每周注药1次,4次为1个疗程。记录2组胸腔积液变化,观察症状、体征、不良反应和一般状况等情况。结果联合组有效率81.8%(18/22);单药组25例中12例有效,有效率48.0%(12/25),组间差异有统计学意义(P〈0.05);联合组生活质量改善率为63.6%(14/22),单药组为32.0%(8/25),组间差异有统计学意义(P〈0.05)。联合组发热发生率为54.5%(12/22),单药组为10.2%(3/25),组间差异有统计学意义(P〈0.05),但所有患者发热均为自限性,不伴有上呼吸道感染症状和局部体征。结论重组人p53腺病毒联合顺铂注射液治疗肺癌所致胸腔积液疗效好,能有效地控制胸腔积液,明显改善患者的生活质量。
出处 《中国医药》 2011年第11期1340-1341,共2页 China Medicine
基金 河北省唐山市科学技术研究与发展计划(08130229b)
  • 相关文献

参考文献7

  • 1袁亚军.胸腔穿刺引流联合岩舒注射液治疗恶性胸腔积液疗效观察[J].中国药房,2007,18(24):1891-1892. 被引量:13
  • 2Kasahara K,Shibata K,Shintani H,et al. Randomized phase II trim of 0K-432 in patients with malignant pleural effusion due to non- small cell lung cancer. Anticancer Res,2006,26(2B) :1495-1499.
  • 3彭朝晖,张晓志.国外重组腺病毒-p53制品对肿瘤基因治疗临床研究的概况[J].中华医学杂志,2003,83(23):2098-2100. 被引量:37
  • 4Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellu- lar damage. Oncogene,2003,22(22) :3431-3440.
  • 5Frank DK. C, ene therapy for head and neck cancer. Surg Oncol Clin N Am,2002,11(3) :589-606,vi-vii.
  • 6Horio Y, Hasegawa Y, Sekido Y, et al. Synergistic effects of adeno- vires expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther,2000,7 (4) :537 -544.
  • 7Inoue A, Narumi K, Matsubara N, et al. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of an- ti-cancer drags in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett,2000,157 ( I ) : 105-112.

二级参考文献28

  • 1陈衍智,李萍萍,杨丽芳,刘培红.白细胞介素Ⅱ联合顺铂治疗恶性胸腔积液[J].临床肿瘤学杂志,2004,9(4):337-339. 被引量:21
  • 2邓述恺,邓俊,黄忠碧,杨大运.胸腔置管引流并灌注白细胞介素Ⅱ联合顺铂治疗肺癌恶性胸腔积液[J].中国现代医学杂志,2005,15(21):3303-3305. 被引量:21
  • 3毛慧生,刘洪■,李川,宋燕爽,孙慧,冯玉梅,苏明秀.苦参碱对肿瘤细胞恶性表型及免疫功能的调控作用[J].中国肿瘤临床,1996,23(11):799-803. 被引量:59
  • 4Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol, 1998, 16:2221-2232.
  • 5Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst, 1999, 91:763-771.
  • 6Chada S, Mhashilkar A, Roth JA, et al. Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel, 2003, 6:169-173.
  • 7Martin B, Bradly GW. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res,1999, 59: 1391-1399.
  • 8Martin LS, Young RS. p53 regulation of DNA excision repair pathways. Mutagenesis, 2002, 17: 149-156.
  • 9Introgen′s Intrabronchial Advexin therapy demonstrates safety and clinical activity in bronchoalveolar lung cancer. Introgen Therapeutics, Inc. News Release, 2003-06-02.
  • 10Phase 2 breast cancer study shows clinical responses in 90 percent of patients treated with Introgen′s Advexin therapy. Introgen Therapeutics, Inc. News Release, 2003-06-02.

共引文献48

同被引文献38

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部